Building a Sequencing Roadmap at Diagnosis in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, examine how clinicians can proactively design a sequencing strategy starting at diagnosis. They discuss mapping out multiple lines of therapy, identifying which patients are best suited for combination vs monotherapy, and how real-world factors influence these decisions. The discussion also highlights the importance of patient counseling, including conversations around long-term goals, toxicity management, and the shift toward a more strategic, rather than reactive, treatment approach.